3 Overlooked Trends Shaping 2026

InvestorPlace | January 11, 2026 at 05:17 PM UTC
Bullish 76% Confidence Unanimous Agreement
Read Original Article

Key Points

  • Rate cuts: Wall Street expects only two Fed rate cuts in 2026, but White House rhetoric and Trump's dovish Fed chair preference suggest more cuts likely; Rocket Companies (RKT) positioned to benefit from mortgage refinancing wave if rates fall below 6%
  • Gene editing: FDA introduced accelerated approval pathway in November allowing gene-editing therapies to skip large randomized trials; Crispr Therapeutics (CRSP) revenues projected to surge from $9.4M in 2025 to $112M in 2026 and potentially $1B by 2030
  • Domestic security: Evolv Technologies (EVLV) produces AI-powered weapon detection gates for public spaces; company has improved after 2024 management changes and is DHS-approved, with Wall Street underestimating 2026 growth above 15% consensus

AI Summary

Market Summary: 3 Overlooked Trends Shaping 2026

Key Thesis

InvestorPlace analyst Tom Yeung warns that "hindsight investing"—betting on 2024-2025's AI and tech winners—may fail in 2026. Senior Analyst Louis Navellier has turned cautiously bearish, predicting a potential "hidden crash" as trillion-dollar tech giants show collapsing earnings momentum.

Three Overlooked Investment Trends

1. Accelerated Rate Cuts

  • Wall Street expects only two rate cuts in 2026, but betting markets project 3-4 cuts
  • President Trump seeks faster rate reductions, calling Fed Chair Powell "TOO LATE"
  • Pick: Rocket Cos. Inc. (RKT) – A-rated mortgage refinancing leader
  • Trump ordered $200 billion mortgage bond purchase to lower borrowing costs
  • Mortgage rates could fall below 6% if Fed cuts rates below 2.75%

2. Gene Editing Technologies

  • FDA unveiled accelerated approval pathway in November 2025, allowing companies to skip large randomized trials
  • Pick: Crispr Therapeutics AG (CRSP) – B-rated, founded by CRISPR/Cas9 inventors
  • Revenue projections: $9.4M (2025) → $112M (2026) → $273M (2027) → $1B (2030)
  • First sickle cell gene therapy recently approved; Trump administration supportive

3. Domestic Security Technology

  • Pick: Evolv Technologies Holdings Inc. (EVLV) – B-rated weapon detection systems
  • Uses AI-powered, unintrusive screening gates for stadiums, schools, and public spaces
  • DHS-approved; pursuing airport approvals
  • New CEO implemented subscription model after 2024 scandal
  • Wall Street forecasts 15% growth; analyst expects outperformance

Market Implications

Yeung draws parallels to previous crashes (1987, 2000, 2008), warning that lagging indicators mask underlying weaknesses in current AI-driven trends.

Model Analysis Breakdown

Model Sentiment Confidence
GPT-5-mini Bullish 75%
Claude 4.5 Haiku Bullish 68%
Gemini 2.5 Flash Bullish 85%
Consensus Bullish 76%